Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties

Phytomedicine

Volumn 15, Issue 1-2, 2008, Pages 2-15

  Hattesohl, Miguel ^a   Feistel, Björn ^b   Sievers, Hartwig ^c   Lehnfeld, Romanus ^c   Hegger, Mirjam ^a   Winterhoff, Hilke ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Plantextrakt GmbH and Co KG   (Germany)

^c PhytoLab GmbH   (Germany)

Author keywords

Antidepressant; Anxiolytic; Elevated plus maze; Locomotor activity; Myorelaxant; Sedative; Valeriana officinalis L.s.l.

Indexed keywords

ALCOHOL; DIAZEPAM; ETHER; METHANOL; PHYTOFIN VALERIAN 368; SOLVENT; UNCLASSIFIED DRUG; VALERIAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; DRUG ISOLATION; EVALUATION; FEMALE; FORCED SWIMMING TEST; LOCOMOTION; MALE; MAZE TEST; MOUSE; NERVOUSNESS; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; SLEEP DISORDER; SPRAGUE DAWLEY RAT; TASK PERFORMANCE; TRANQUILIZING ACTIVITY; VALERIANA OFFICINALIS;

ANESTHETICS, INHALATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ETHER, ETHYL; FEMALE; HYPNOTICS AND SEDATIVES; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; MUSCLE CONTRACTION; PLANT EXTRACTS; RATS; VALERIAN;

MUS; RATTUS; VALERIANA; VALERIANA OFFICINALIS;

EID: 37549018503     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2007.11.027     Document Type: Article

References (62)

1. Aktories K., Förstermann U., Hofmann F., and Starke K. Allgemeine und spezielle Pharmakologie und Toxikologie (2005), Elsevier GmbH, München
2. Andreatini R., and Leite J.R. Effect of valepotriates on the behavior of rats in the elevated plus-maze during diazepam withdrawal. Eur. J. Pharmacol. 260 2-3 (1994) 233-235
3. Andreatini R., Sartori V.A., Seabra M.L., and Leite J.R. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother. Res. 16 7 (2002) 650-654
4. Balderer G., and Borbely A.A. Effect of valerian on human sleep. Psychopharmacology (Berlin) 87 4 (1985) 406-409
5. 6-cyclohexyladenosine binding to rat cortical membranes by an hydroalcoholic extract of Valeriana officinalis. Med. Sci. Res. 17 (1989) 639-640
6. Bodesheim U., and Hölzl J. [Isolation and receptor binding properties of alkaloids and lignans from Valeriana officialis L. Pharmazie 52 5 (1997) 386-391
7. Boissier J.R., and Simon P. L′utilisation du test de la traction, (Test de JULOU-COURVOISIER) pour l′etude des psycholeptiques. Therapie 15 (1960) 1170-1174
8. Borsini F. Role of the serotonergic system in the forced swimming test. Neurosci. Biobehav. Rev. 19 3 (1995) 377-395
9. Cavadas C., Araujo I., Cotrim M.D., Amaral T., Cunha A.P., Macedo T., and Ribeiro C.F. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung/Drug Res. 45 7 (1995) 753-755
10. Committee on Herbal Medicinal Products (HMPC/EMEA). Community Monograph on Valeriana officinalis L, radix, 2006.
11. Cropley M., Cave Z., Ellis J., and Middleton R.W. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother. Res. 16 1 (2002) 23-27
12. Dietz B.M., Mahady G.B., Pauli G.F., and Farnsworth N.R. Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro. Brain Res. Mol. Brain Res. 138 2 (2005) 191-197
13. Donath F., Quispe S., Diefenbach K., Maurer A., Fietze I., and Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33 2 (2000) 47-53
14. Donovan J.L., DeVane C.L., Chavin K.D., Wang J.S., Gibson B.B., Gefroh H.A., and Markowitz J.S. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab. Dispos. 32 12 (2004) 1333-1336
15. Dorn M. [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study]. Forsch Komplementarmed Klass Naturheilkd 7 2 (2000) 79-84
16. ESCOP. ESCOP Monographs (2003), Thieme, Stuttgart
17. Fernandez S., Wasowski C., Paladini A.C., and Marder M. Sedative and sleep-enhancing properties of linarin, a flavonoid-isolated from Valeriana officinalis. Pharmacol. Biochem. Behav. 77 2 (2004) 399-404
18. Fernandez S.P., Wasowski C., Paladini A.C., and Marder M. Synergistic interaction between hesperidin, a natural flavonoid, and diazepam. Eur. J. Pharmacol. 512 2-3 (2005) 189-198
19. 3H]GABA. Rev. Port. Farm. 46 2 (1996) 74-77
20. File S.E., Mabbutt P.S., and Hitchcott P.K. Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology (Berlin) 102 1 (1990) 98-101
21. Gerhard U., Linnenbrink N., Georghiadou C., and Hobi V. Vigilance-decreasing effects of 2 plant-derived sedatives. Schweiz. Rundsch. Med. Prax. 85 15 (1996) 473-481
22. Glass J.R., Sproule B.A., Herrmann N., Streiner D., and Busto U.E. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J. Clin. Psychopharmacol. 23 3 (2003) 260-268
23. Gries D.A., Condouris G.A., Shey Z., and Houpt M. Anxiolytic-like action in mice treated with nitrous oxide and oral triazolam or diazepam. Life Sci. 76 15 (2005) 1667-1674
24. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Khan I.A., and Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 77 5 (2005) 415-426
25. Gutierrez S., Ang-Lee M.K., Walker D.J., and Zacny J.P. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol. Biochem. Behav. 78 1 (2004) 57-64
26. Hall C.S. Emotional behavior in the rat: I. Defecation and urination as measures of individual differences in emotionality. J. Comp. Psychol. 18 (1934) 385-403
27. Hallam K.T., Olver J.S., McGrath C., and Norman T.R. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Hum. Psychopharmacol. 18 8 (2003) 619-625
28. Hendriks H., Bos R., Allersma D.P., Malingre T.M., and Koster A.S. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med. 42 1 (1981) 62-68
29. Hiller, K.O., Kato, G., 1996. Anxiolytic Activity of Psychotropric Plant Extracts. I. Test of Ethanolic Valeriana Extract STEI Val. Posterpräsentation: 44th Annual Congress of the Society for Medical Plant Research 1996.
30. Hiller K.O., and Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.: behavioural and anticonvulsant properties. Phytother. Res. 10 (1996) 145-151
31. Kakinohana M., Taira Y., Kakinohana O., and Okuda Y. The inhibition of lidocaine metabolism by various barbiturates in rat hepatic microsome. Masui 47 11 (1998) 1302-1310
32. Kamm-Kohl A.V., and Jansen W. Moderne Baldriantherapie gegen nervöse Störungen. Die Med. Welt 35 (1984) 1450-1454
33. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pezzola A., Reggio R., Muller C.E., Fuxe K., Goldberg S.R., Popoli P., and Ferre S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 7 (2003) 1281-1291
34. Kuhlmann J., Berger W., Podzuweit H., and Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Pharmacopsychiatry 32 6 (1999) 235-241
35. Leathwood P.D., Chauffard F., Heck E., and Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol. Biochem. Behav. 17 1 (1982) 65-71
36. Leuschner J., Muller J., and Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung 43 6 (1993) 638-641
37. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin) 92 2 (1987) 180-185
38. Mandryk M., Fidecka S., Poleszak E., and Malec D. Participation of adenosine system in the ketamine-induced motor activity in mice. Pharmacol. Rep. 57 1 (2005) 55-60
39. Marder M., Viola H., Wasowski C., Fernandez S., Medina J.H., and Paladini A.C. 6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol. Biochem. Behav. 75 3 (2003) 537-545
40. Mennini T., and Bernasconi P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 64 4 (1993) 291-300
41. Müller C.E., Schumacher B., Brattstrom A., Abourashed E.A., and Koetter U. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Sci. 71 16 (2002) 1939-1949
42. Ortiz J.G., Nieves-Natal J., and Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem. Res. 24 11 (1999) 1373-1378
43. Ortiz J.G., Rassi N., Maldonado P.M., Gonzalez-Cabrera S., and Ramos I. Commercial valerian interactions with [(3)H]Flunitrazepam and [(3)H]MK-801 binding to rat synaptic membranes. Phytother. Res. (2006)
44. Patterson J.P., Markgraf C.G., Cirino M., and Bass A.S. Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds. J. Pharmacol. Toxicol. Methods 52 1 (2005) 159-167
45. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 3 (1985) 149-167
46. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 5604 (1977) 730-732
47. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 4 (1978) 379-391
48. Riedel E., Hansel R., and Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives. Planta Med. 46 4 (1982) 219-220
49. Santos M.S., Ferreira F., Cunha A.P., Carvalho A.P., and Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med. 60 3 (1994) 278-279
50. Santos M.S., Ferreira F., Cunha A.P., Carvalho A.P., Ribeiro C.F., and Macedo T. Synaptosomal GABA release as influenced by valerian root extract - involvement of the GABA carrier. Arch. Int. Pharmacodyn. Ther. 327 2 (1994) 220-231
51. Santos M.S., Ferreira F., Faro C., Pires E., Carvalho A.P., Cunha A.P., and Macedo T. The amount of GABA present in aqueous extracts of valerian is sufficient to account for [3H]GABA release in synaptosomes. Planta Med. 60 5 (1994) 475-476
52. Schramm E., Hohagen F., Kappler C., Grasshoff U., and Berger M. Mental comorbidity of chronic insomnia in general practice attenders using DSM-III-R. Acta Psychiatr. Scand. 91 1 (1995) 10-17
53. Schulz H., Jobert M., and Hübner W.D. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine 5 6 (1998) 449-458
54. Schulz V., and Hänsel R. Rationale Phytotherapie (2004), Springer, Berlin, Heidelberg, NY
55. Schumacher B., Scholle S., Holzl J., Khudeir N., Hess S., and Muller C.E. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J. Nat. Prod. 65 10 (2002) 1479-1485
56. Shinomiya K., Fujimura K., Kim Y., and Kamei C. Effects of valerian extract on the sleep-wake cycle in sleep-disturbed rats. Acta Med. Okayama 59 3 (2005) 89-92
57. Simmen U., Saladin C., Kaufmann P., Poddar M., Wallimann C., and Schaffner W. Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John's wort. Planta Med. 71 7 (2005) 592-598
58. Vorbach E.U., Görteleyer R., and Brüning J. Therapie von Insomnien-Wirksamkeit und Verträglichkeit eines Baldrianpräparats. Psychopharmakotherapie 3 3 (1996) 109-115
59. Wagner H., Jurcic K., and Schaette R. Comparative studies on the sedative action of Valeriana extracts, valepotriates and their degradation products. Planta Med. 39 4 (1980) 358-365 (authors's translation)
60. Wasowski C., Marder M., Viola H., Medina J.H., and Paladini A.C. Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichii. Planta Med. 68 10 (2002) 934-936
61. Yuan C.S., Mehendale S., Xiao Y., Aung H.H., Xie J.T., and Ang-Lee M.K. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth. Analg. 98 2 (2004) 353-358 Table of contents
62. Ziegler G., Ploch M., Miettinen-Baumann A., and Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia - a randomized, double-blind, comparative clinical study. Eur. J. Med. Res. 7 11 (2002) 480-486